From Pathway to Prescription in Alopecia Areata. Dive into the latest insights on disease pathogenesis, emerging targeted therapies ... Show more
Immunology Learning Nexus
Immunology Learning Nexus
Pharma's next cash cows could be specialized treatments: The key to future profits may be customized treatments tailored to patients' genes and lifestyles.
axios.com/2026/11/02/pharma-profits-specialized-treatments-blockbuster-drugs
Starlink controversy could give this TSX-listed company an edge, analyst says: The Week in Stocks: Which sector is a bright spot as tech tanks ...
financialpost.com/investing/the-week-in-stocks
Zepbound grew 174.9% in 2025, the fastest rate among the top 10 drugs: Seven of the best-selling drugs of 2026 from GEN's top 10, ranked by 2025 sales ...
qz.com/best-selling-drugs-2026-2025-sales
What's Going On With Bristol-Myers Squibb Stock Thursday? - Bristol-Myers Squibb (NYSE:BMY)
benzinga.com/markets/earnings/26/10/62710416/bristol-myers-squibb-says-ai-is-already-speeding-up-drug-research-and-its-measuring-the-impact
Anthropic is running its own drug programs after acquiring a one-person biotech: Anthropic released early results from drug development work with six partners ...
qz.com/anthropic-mithril-medicine-acquisition-drug-programs-102826
Democrats say Trump increased investments in drugmakers that were given Medicare exemptions
pbs.org/newshour/politics/democrats-say-trump-increased-investments-in-drugmakers-that-were-given-medicare-exemptions
yicaiglobal.com Oct 28
China’s Hengrui Pharma Soars Amid Strong Earnings Growth in First Nine Months Driven by Innovative Drug Business
yicaiglobal.com/news/chinas-hengrui-pharma-soars-amid-strong-earnings-growth-in-first-nine-months-driven-by-innovative-drug-business
STAT Oct 27
Roche gets a lung cancer win with its KRAS drug divarasib: Roche drug, which inhibits G12C KRAS mutations in second-line advanced non-small cell lung cancer ...
statnews.com/2026/10/26/roche-kras-drug-divarasib-lung-cancer-treatment-win/
Paid articlePaywall
The Market May Be Too Pessimistic About This 4-Star Dividend Stock: Despite a looming patent cliff, a strong drug pipeline and 4.1% yield give investors reasons ...
morningstar.com/stocks/market-may-be-too-pessimistic-about-this-4-star-dividend-stock
Britain’s ‘longest medicine shortage on record’ leaves 60% of patients without crucial drug – what can you do?
thesun.co.uk/health/40633524/britain-longest-drug-shortage-hrt-menopause/
Bristol Myers Reverses Lower Despite Double Phase 3 Win, As A Key Rival Crashes: Bristol Myers Squibb stock fell despite two Phase 3 wins on Monday in lung ...
investors.com/news/technology/bristol-myers-squibb-stock-continuem-therapeutics-stock-ipf-gep-nets/
Barron's Oct 12
Bristol Myers Stock Is Rising on a Double Dose of Good News: Bristol Myers Squibb is making a $4.1 billion bet on radiopharmaceutical cancer drugs ahead of a ...
barrons.com/articles/bristol-myers-squibb-stock-drug-trials-e2bb2683
Paid articlePaywall During Rheumatoid Arthritis Awareness Month, explore education designed to help clinicians move beyond reactive care and support better long-term outcomes with ... Show more
Immunology Learning Nexus
Immunology Learning Nexus
This $3 Biotech Could Be Worth $11.45, Analyst Says - Perspective Therapeutics (AMEX:CATX)
benzinga.com/analyst-stock-ratings/initiation/26/09/61877282/this-3-biotech-could-be-worth-11-45-analyst-says
Novo to use Anthropic’s Claude to advance AI drug discovery: The deal underscores a broader push by drugmakers to integrate AI across research and development to ...
euronews.com/health/2026/09/16/danish-pharma-giant-novo-to-use-anthropics-claude-to-advance-ai-drug-discovery
Barron's Sep 03
Revisiting Stock Picks Dexcom, Bristol Myers Squibb, Quanta Services: Technical indicators have turned bullish for the three stocks.
barrons.com/articles/revisiting-stock-picks-dexcom-bristol-myers-quanta-services-charts-8ca397e2
Paid articlePaywall
Exclusive | Drugmakers Halt Autoimmune Trials After Deaths, Life-Threatening Side Effects
wsj.com/health/pharma/drugmakers-halt-autoimmune-trials-after-deaths-life-threatening-side-effects-14e786fd
Paid articlePaywallKey FactsSerious Safety Events Halt Autoimmune CAR-T Trials
Sep 4, 2026 · Reading time: ~45 sec.
Summary created with AI assistance · Source: wsj.com
Summary created with AI assistance · Source: wsj.com
- In early June, Bristol Myers told regulators, researchers and patient groups about a pause over life-threatening side effects; public disclosure came three months later.
- Novartis confirmed a similar pause in August after an analyst found it, then reported three study-participant deaths one week later.
- Novartis has enrolled more than 500 patients across eight autoimmune trials of rap-cel; Bristol Myers halted other studies beyond lupus.
- Novartis’s cases involved a rare immune-system overreaction; Bristol Myers cited ICANS, a form of brain inflammation.
Every piece of information is critical.— Dr. Anca Askanase, rheumatology chief at the Hospital for Special Surgery in New York City, commenting on the need for full disclosure and detail surrounding the paused autoimmune-trial data.
Merck adds $43 billion after cancer vaccine trial win : Merck added billions in a single day after its Moderna-partnered cancer vaccine cleared a major hurdle.
star-telegram.com/news/business/article316987770.html
Barron's Aug 04
More Biotech M&A Is Coming, Whether an AstraZeneca-Bristol Myers Deal Happens or Not
barrons.com/articles/biotech-mergers-astrazeneca-bristol-myers-stock-e9362d24
Paid articlePaywall
Bristol Myers Squibb plans $2.3B manufacturing plant in Houston: Bristol Myers Squibb will build a massive advanced manufacturing and life sciences facility in ...
houstonchronicle.com/business/article/bristol-myers-squibbs-houston-biotech-22381760.php
STAT Aug 14
Pharmalittle: We’re reading about a lawsuit over lab tests for meds, a Bristol myeloma drug, and more
statnews.com/pharmalot/2026/08/14/lab-tests-lawsuit-bristol-multiple-myeloma-drug-approved/
Paid articlePaywall
Lawsuit against Bristol Myers over delayed cancer drug is revived: A U.S. federal appeals court said a judge erred in dismissing a $6.7 billion lawsuit accusing ...
reuters.com/legal/government/lawsuit-against-bristol-myers-over-delayed-cancer-drug-is-revived-2026-08-13/
Is a mega-merger in the works in the pharmaceutical sector? After a recent focus on acquisitions aimed at strengthening existing pipelines ... Show more
AstraZeneca stock sinks on reports of merger talks with Bristol Myers Squibb: A combination of the two pharmaceutical companies could create an entity valued at ...
qz.com/astrazeneca-bristol-myers-squibb-merger-talks-080326
Pharma investors reeled this week from reports that AstraZeneca held merger talks with U.S. rival Bristol Myers Squibb, a move that would break from Big ... Show more
AstraZeneca may buck a decade of pharma strategy to buy U.S. scale: Reports of preliminary talks between AstraZeneca and Bristol Myers Squibb moved shares and ...
cnbc.com/2026/08/06/astrazeneca-bristol-myers-merger-talks.html
Pfizer beats earnings estimates, targets $2.5 billion in additional cost cuts: GENEVA: Pfizer on Tuesday reported better-than-expected second-quarter results ...
arabnews.com/node/2653354/world
AstraZeneca could be Britain’s next loss: AstraZeneca’s deal talks with US-headquartered Bristol Myers Squibb, which Semafor confirms remain active ...
semafor.com/article/08/04/2026/astrazeneca-could-be-britains-next-loss
Struggling to make sense of AstraZeneca-BMS: All about oncology? A cardio workout? Patent-cliff avoidance? American dreaming?
ft.com/content/eddbdc29-5206-4c79-9ea7-f1a06ff040f1
Paid articlePaywall Barron's Jun 25
Revisiting Stock Picks Intel, Progressive, Bristol Myers Squibb: Technical indicators show encouraging signs for the three stocks.
barrons.com/articles/revisiting-stock-picks-intel-progressive-bristol-myers-squibb-7818ee5e
Paid articlePaywall
CNBC Jun 01
Bristol Myers Squibb CEO on $15B deal with China's Hengrui Pharma: Bristol Myers Squibb CEO Chris Boerner sits down with CNBC's Angelica Peebles at the ...
cnbc.com/video/2026/06/01/bristol-myers-squibb-ceo-on-15b-deal-with-chinas-hengrui-pharma.html
Wall Street's Most Accurate Analysts Give Their Take On 3 Healthcare Stocks Delivering High-Dividend Yiel
benzinga.com/analyst-stock-ratings/price-target/26/05/52868348/wall-streets-most-accurate-analysts-give-their-take-on-3-healthcare-stocks-delivering-high-dividend-yields
Bristol Myers Squibb signs $15.2B licensing deal with Hengrui: The agreement covers 13 early-stage programs in oncology, hematology, and immunology ...
qz.com/bristol-myers-squibb-hengrui-pharma-licensing-deal-051226
Bristol Myers Squibb considering building $1B pharma plant in Houston: Global pharmaceutical company Bristol Myers Squibb is considering building a $1B ...
houstonchronicle.com/business/article/bristol-myers-squibb-houston-22261394.php
Investors often look for dividend-paying stocks during uncertain markets, especially companies with strong cash flow and steady shareholder payouts ... Show more
Bristol Myers Squibb Logs Higher Sales, Profit: The biopharmaceutical company said first-quarter results were boosted by its portfolio of newer treatments for ...
wsj.com/health/pharma/bristol-myers-squibb-logs-higher-sales-profit-e01468fa
Paid articlePaywall
Gilead to buy Germany’s Tubulis for up to US$5 billion to boost cancer pipeline: Gilead said on Tuesday it would acquire Germany-based Tubulis GmbH for up to ...
bnnbloomberg.ca/business/2026/04/07/gilead-to-buy-germanys-tubulis-for-up-to-us5-billion-to-boost-cancer-pipeline/
Trump unveils 100% tariff that could hit some patented drugs this year: President Donald Trump has signed an executive order that could slap long-threatened ...
apnews.com/article/trump-tariffs-pharmaceutical-drugs-59ed7821faa5b52e2752c09edbbbf0ca
Trump unveils 100 percent tariff on drugs to push for pharmaceutical deals: US president has said that he will use tariffs to bring down costly medical drugs ...
aljazeera.com/news/2026/4/2/trump-unveils-100-percent-tariff-on-drugs-to-push-for-pharmaceutical-deals
Key FactsTrump Enforces Full Tariffs on Select Drug Imports
Apr 2, 2026 · Reading time: ~30 sec.
Summary created with AI assistance · Source: 9news.com.au
Summary created with AI assistance · Source: 9news.com.au
- President Trump has imposed a 100 percent tariff on certain patented imported drugs to encourage domestic manufacturing.
- The tariffs will begin after 120 days for large companies, with smaller firms receiving a 180-day grace period.
- Exemptions apply to companies joining the 'Most Favoured Nation' program or relocating production to the US with reduced tariffs.
- Australia faces significant effects due to $1.6 billion in pharmaceutical exports lacking a dedicated US trade agreement.
Barclays names 2 drug stocks investors should own in 2026 | LLY: Barclays just told investors exactly where to put their money in 2026.
thestreet.com/investing/stocks/barclays-names-2-drug-stocks-investors-should-own-in-2026
Donald Trump still isn’t done with Britain’s NHS: U.S. officials are quietly laying the groundwork to revisit the U.K.’s drug pricing deal before the end of the ...
politico.eu/article/donald-trump-us-uk-national-health-service-nhs-medicine-price/
STAT Feb 09
Eli Lilly to buy Orna Therapeutics for $2.4 billion: Eli Lilly will pay up to $2.4 billion for the biotechnology firm, the latest in a string of deals that the ...
statnews.com/2026/02/09/eli-lilly-buys-orna-therapeutics-in-vivo-car-t/
Paid articlePaywall STAT Feb 02
Why Bristol Myers Squibb believes a decades-old drug can treat Alzheimer’s : BMS faces a $20 billion annual revenue loss as its biggest drugs lose patent ...
statnews.com/2026/02/02/bristol-myers-squibb-facing-patent-cliff-big-bet-on-cobenfy/
Paid articlePaywall
Johnson & Johnson announces drug pricing deal with Trump administration: Johnson & Johnson said late Thursday it will lower prices for certain prescription ...
thehill.com/policy/healthcare/5681535-johnson-johnson-trump-drug-prices/
Aktis Oncology: Hot US IPO - | the background: Aktis Oncology aims for Nasdaq listing, Eli Lilly to become major shareholder.
deraktionaer.de/artikel/pharma-biotech/aktis-oncology-heisser-us-boersengang-die-hintergruende-20393148.html
WATCH: Trump announces 9 pharmaceutical companies will lower drug prices: Pharmaceutical companies Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech ...
pbs.org/newshour/health/watch-live-trump-expected-to-make-announcement-about-lowering-drug-prices
Bristol-Myers Squibb: Contrarian Buy For Dividend Hunters, Despite Mounting Growth Headwinds
seekingalpha.com/article/4855537-bristol-myers-squibb-contrarian-buy-for-dividend-hunters-despite-mounting-growth-headwinds
Paid articlePaywall Best Healthcare Companies to Own: 2026 Edition: These companies largely earn their competitive advantage from intangible assets, and their stocks are great ...
spr.ly/6010COlsq
Bristol-Myers Squibb: Pharma Giant Still Undervalued And Printing Cash Despite Patent Cliff
seekingalpha.com/article/4855220-bristol-myers-squibb-pharma-giant-still-undervalued-and-printing-cash-despite-patent-cliff
Paid articlePaywall
A delayed clinical trial actually boosted Bristol Myers Squibb’s stock. Here’s why.
marketwatch.com/story/a-delayed-clinical-trial-actually-boosted-bristol-myers-squibbs-stock-heres-why-b831896f
Paid articlePaywall
Bristol-Myers Squibb’s Irish entity slashes dividend to parent firm from $6bn in 2023
businesspost.ie/companies/bristol-myers-squibbs-irish-entity-slashes-dividend-to-parent-firm-from-6bn-in-2023/
Paid articlePaywall Barron's Dec 03 25
Bristol Myers Squibb Stock Climbs on Alzheimer’s Trial Update. What to Know.: Bristol Myers Squibb is testing its antipsychotic drug Cobenfy for the treatment of ...
barrons.com/articles/bristol-myers-squibb-alzheimers-trial-cobenfy-37ce479a
Paid articlePaywallBristol Myers must face $6.7 billion lawsuit over delayed cancer drug, US judge rules
reuters.com/world/bristol-myers-must-face-67-billion-lawsuit-over-delayed-cancer-drug-us-judge-2025-12-01/
Barron's Nov 20 25
Buy Bristol Myers Squibb Stock. The Drugmaker Is Too Cheap to Ignore.
barrons.com/articles/wp-bar-0001507322
Paid articlePaywall
US stock markets continue their recovery: Technology stocks very strong: The Nasdaq Composite climbed a strong 2.7 percent. Hopes for another interest rate cut ...
diepresse.com/20343390/us-boersen-setzen-erholungsschub-fort-technologiewerte-sehr-stark
Closing bell: Dow & Co. with a strong start, Merck and Alphabet rally: US stock markets rise after hopes of an interest rate cut; tech and pharmaceutical stocks ...
deraktionaer.de/artikel/aktien/schlussglocke-dow-co-mit-starkem-auftakt-merck-und-alphabet-haussieren-20390886.html
Bayer: Asundexian impresses in study and becomes a beacon of hope: In a new stroke study, Bayer is impressing with a drug that caused the company a significant ...
faz.net/aktuell/wirtschaft/unternehmen/bayer-asundexian-ueberzeugt-in-studie-und-wird-hoffnungstraeger-110790576.html
Mega share price jump at Bayer! Is the DAX laggard finally taking off?: Bayer shares rise due to positive Phase III trial of stroke drug Asundexian ...
boerse-online.de/nachrichten/aktien/durchbruch-bei-bayer-was-der-heutige-kurssprung-der-dax-aktie-wirklich-bedeutet-20390856.html
Evotec: Milestone for pharmaceutical giant - | Stock shows signs of life: Evotec receives $5 million from Bristol Myers Squibb.
deraktionaer.de/artikel/pharma-biotech/evotec-meilenstein-von-pharma-giganten-aktie-sendet-lebenszeichen-20390208.html
BioNTech: Hammer deal - share price jumps: BioNTech signs billion-euro deal with Bristol-Myers Squibb for cancer drug BNT327.
deraktionaer.de/artikel/pharma-biotech/biontech-hammer-deal-aktie-mit-kurssprung-20381143.html
Key FactsBiontech Partners with US Firm to Advance Cancer Drug
Jun 3, 2025 · Reading time: ~45 sec.
Summary created with AI assistance · Source: berliner-zeitung.de
Summary created with AI assistance · Source: berliner-zeitung.de
- Biontech and Bristol Myers Squibb signed an agreement for the global development and marketing of the cancer drug candidate BNT327.
- The collaboration aims to accelerate progress and maximize the therapeutic potential of the drug.
- Payments totaling close to $11 billion are planned to support Biontech through 2028.
- Following the deal, Biontech's shares surged over 20 percent and analysts continue to recommend buying the stock.
Our collaboration with BMS, a pioneer in immuno-oncology, aims to accelerate and broadly expand the development of BNT327 to realize its full potential.— Ugur Sahin, CEO of Biontech, on the collaboration with Bristol Myers Squibb.
Bristol Myers' Cobenfy fails in key study as add-on treatment for schizophrenia: Bristol Myers Squibb said on Tuesday its drug Cobenfy failed to show a ...
reuters.com/business/healthcare-pharmaceuticals/bristol-myers-cobenfy-fails-meet-main-goal-add-on-treatment-schizophrenia-2025-04-22/
